Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829413 · ClinicalTrials.gov registry record · Phase 3
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
A Phase 3 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 3
- Development phase
- 353
- Enrollment target
NCT00829413 is a Phase 3 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 353 participants.
The verdict
NCT00829413, a Phase 3 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 353 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the Sensitivity and Specificity of SonoVue®-enhanced ultrasound is superior to that of unenhanced ultrasound for the characterization of benign versus malignant FLLs using final diagnosis based on histology or combined imaging (CE-CT and/or CE MRI)/clinical data as truth standard.
Interventions
- DRUG SonoVue®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829413
The ClinicalTrials.gov registry entry for NCT00829413 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SonoVue® is the first listed.
NCT00829413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829413 about?
NCT00829413 is a clinical study titled "SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization". The purpose of this study is to demonstrate the Sensitivity and Specificity of SonoVue®-enhanced ultrasound is superior to that of unenhanced ultrasound for the characterization of benign versus malignant FLLs using final diagnosis based on histology or combined imaging (CE-CT and/or CE MRI)/clinica...
What is the current status of trial NCT00829413?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 353 participants. The study started on 2010-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00829413?
The interventions under investigation include: SonoVue® (DRUG).
Who is sponsoring clinical trial NCT00829413?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.